Novo Nordisk A/S
- Country
- ๐ฉ๐ฐDenmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT05823948
- Locations
- ๐บ๐ธ
Amarillo Medical Specialists, Amarillo, Texas, United States
๐บ๐ธAccellacare_NC, Wilmington, North Carolina, United States
๐บ๐ธDesert Oasis Hlthcr Med Group, Palm Springs, California, United States
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 148
- Registration Number
- NCT05813912
- Locations
- ๐ฒ๐พ
Hospital Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia
๐ฒ๐พUniversiti Teknologi MARA, Sungai Buloh Campus, Sungai Buloh, Selangor, Malaysia
๐น๐ญKing Chulalongkorn Memorial Hospital, Bangkok, Thailand
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
- Conditions
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 330
- Registration Number
- NCT05813925
- Locations
- ๐ฏ๐ต
Seino Internal Medicine Clinic, Koriyama-shi, Fukushima, Japan, Japan
๐ฏ๐ตTsuruma Kaneshiro Diabetes Clinic, Yamato-shi, Kanagawa, Japan
๐ฏ๐ตHeiwadai Hospital, Miyazaki-shi, Miyazaki, Japan
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 107
- Registration Number
- NCT05804162
- Locations
- ๐ฉ๐ช
Parexel International GmbH, Berlin, Germany
A Study to Understand the Distribution of Obesity Classes and Obesity Related Diseases in People With Obesity Across Countries in Czech Republic, Hungary and Poland
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1241
- Registration Number
- NCT05795166
- Locations
- ๐ญ๐บ
Dr. Dozsa Katalin Maria EV, Biatorbรกgy, Hungary
๐ต๐ฑALLMEDICA sp. z o. o., Nowy Targ, Poland
๐ต๐ฑClinmedica Research spzo.o, Skierniewice, Poland
A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT05790681
- Locations
- ๐บ๐ธ
Children's Hosp-Los Angeles, Los Angeles, California, United States
๐บ๐ธNemours Chld Clnc Jacksonville, Jacksonville, Florida, United States
๐บ๐ธUniversity of Virginia, Charlottesville, Virginia, United States
A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 264
- Registration Number
- NCT05784402
- Locations
- ๐จ๐ฆ
Altasciences Clinical Company, Inc, Montreal, Quebec, Canada
๐บ๐ธAltasciences Clinical LA, Inc., Cypress, California, United States
An Observational Study of Patients With Moderate Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 96
- Registration Number
- NCT05779475
- Locations
- ๐บ๐ธ
NYU Langone Health, New York, New York, United States
๐บ๐ธNY Presbyt Hosp-W Cornell Med, New York, New York, United States
๐ธ๐ชNeurologimottagningen Lund, Lund, Sweden
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 53
- Registration Number
- NCT05766709
- Locations
- ๐จ๐ฆ
Altasciences Company Inc., Montreal, Quebec, Canada
Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 675
- Registration Number
- NCT05765890
- Locations
- ๐ฎ๐ณ
Novo Nordisk Investigational Site, Bangalore, India